Home Archives 2011

Yearly Archives: 2011

The January 2012 issue of the Journal of Commercial Biotechnology is now available. Contents include Original Articles, From the Boardroom, From the Classroom, Legal and Regulatory Update, and Book Reviews.

Individual papers are available for purchase. Subscription options are posted at http://commercialbiotechnology.com/about/subscriptions , and you may also request that your librarian subscribe at http://commercialbiotechnology.com/pages/view/library-subscription .

Table of Contents

Editorial

Exciting changes
Yali Friedman

Articles

Bacterial proteins: A new class of cancer therapeutics
Ananda Mohan Chakrabarty
Industrial biotechnology – Markets and industry structure
Gunter Festel, Christian Detzel, Ruth Maas
Options to Change Medicare Payment for Outpatient Prescription Drugs and Biotechnology Products
Thomas Barker, Maia Larsson
The Emergence of Bio-Clusters in Egypt and South Africa
Ramazan Uctu, Nirvana Shanalee Pillay
Patent litigation in India and interim injunctions — An evolving jurisprudence
Rajashree Sharma, Dinesh Kumar Sharma

From the Boardroom

Digital health investment opportunities abound, but standouts deliver disruptive change
G. Steven Burrill
Strategies for Collaboration Agreements Focusing on Innovation
Pamela Cox
Biomarketing strategy and tactics 101 PART I of III
Dimitris Dogramatzis

From the Classroom

The University of Colorado Certificate Program in Bioinnovation and Entrepreneurship: An Interdisciplinary, Cross-Campus Model
Madhavan Parthasarathy, David Forlani, Arlen Meyers

Legal and Regulatory Updates

EU Legal & Regulatory Update
Ewan Grist
Post-Grant Review: The Good, the Bad and the Ugly for Biotechnology Companies
Smitha Uthaman, Deborah Lu, Thomas Kowalski

Book Reviews

Book Review: Constructing and Deconstructing Patents by Irah H. Donner
David B. Orange
Book Review: Plunkett’s Biotech & Genetics Industry Almanac 2012
Barry J. Marenberg

For more information, see the Journal of Commercial Biotechnology at http://CommercialBiotechnology.com

The January 2012 issue of the Journal of Commercial Biotechnology is ready to go to press. The table of contents is posted below. Like what you see? Subscribe or recommend the journal to your library.

Journal of Commercial Biotechnology Vol 18, Issue 1 (2012) (Preview)

Table of Contents

Editorial

Exciting changes
Yali Friedman

 

Articles

Bacterial proteins: A new class of cancer therapeutics
Ananda Mohan Chakrabarty
Industrial biotechnology – Markets and industry structure
Gunter Festel, Christian Detzel, Ruth Maas
Options to Change Medicare Payment for Outpatient Prescription Drugs and Biotechnology Products
Thomas Barker, Maia Larsson
The Emergence of Bio-Clusters in Egypt and South Africa
Ramazan Uctu, Nirvana Shanalee Pillay
Patent litigation in India and interim injunctions — An evolving jurisprudence
Rajashree Sharma, Dinesh Kumar Sharma

 

From the Boardroom

Digital health investment opportunities abound, but standouts deliver disruptive change
G. Steven Burrill
Strategies for Collaboration Agreements Focusing on Innovation
Pamela Cox
Biomarketing strategy and tactics 101 PART I of III
Dimitris Dogramatzis

 

From the Classroom

The University of Colorado Certificate Program in Bioinnovation and Entrepreneurship: An Interdisciplinary, Cross-Campus ModelPDF Restricted Access
Madhavan Parthasarathy, David Forlani, Arlen Meyers

 

Legal and Regulatory Updates

EU Legal & Regulatory Update
Ewan Grist
Post-Grant Review: The Good, the Bad and the Ugly for Biotechnology Companies
Smitha Uthaman, Deborah Lu, Thomas Kowalski

 

Book Reviews

Book Review: Constructing and Deconstructing Patents by Irah H. Donner
David B. Orange
Book Review: Plunkett’s Biotech & Genetics Industry Almanac 2012
Barry J. Marenberg

 

Do you enjoy the Journal of Commercial Biotechnology sample papers and want complete access to journal?

Librarians appreciate input from their constituents — you can use the library suggestion form on the JCB website to let your librarian know that you would like them to subscribe.

As a bonus, if your library purchases an institutional subscription following your referral, they will also get a free book from Logos Press.

Drug Patent Expirations in December 2011

*Drugs may be covered by multiple patents

TradenameApplicantGeneric NamePatent NumberPatent Expiration
OMNICEFAbbottcefdinir4,935,507Dec 4, 2011
AMPYRAAcordadalfampridine5,370,879Dec 6, 2011
AVELOXBayer Hlthcaremoxifloxacin hydrochloride4,990,517Dec 8, 2011
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINERBayer Hlthcaremoxifloxacin hydrochloride4,990,517Dec 8, 2011
ACCOLATEAstrazenecazafirlukast6,143,775Dec 11, 2011
ACCOLATEAstrazenecazafirlukast5,319,097Dec 11, 2011
ACCOLATEAstrazenecazafirlukast5,294,636Dec 11, 2011
MOTRINMcneil Pedibuprofen5,320,855*PEDDec 14, 2011
TROVANPfizertrovafloxacin mesylate5,164,402Dec 18, 2011
PALLADONEPurdue Pharma Lphydromorphone hydrochloride5,968,551Dec 24, 2011
PALLADONEPurdue Pharma Lphydromorphone hydrochloride6,294,195Dec 24, 2011
MYCAMINEAstellasmicafungin sodium5,376,634Dec 27, 2011
PRIALTAzur Pharma Iiziconotide5,859,186Dec 30, 2011

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.

Courtesy of DrugPatentWatch.com

BiotechBlog and the Journal of Commercial Biotechnology are proud to serve as media sponsors for the 3rd Annual Health Outcomes and Pharmacoeconomics Research conference:

Event Date: 30-31 Jan 2012
Location: Philadelphia, PA, United States

Key conference speakers:
Ari Gnanasakthy
Head, PRO Excellence, Novartis Pharmaceuticals, Inc.
Rami Ben-Joseph, PhD
Vice President, Health Outcomes and Pharmacoeconomics, Endo Pharmaceuticals
Betsy J. Lahue, M.P.H.
Vice President, Health Economics and Outcomes Research, BD
Dr. Omar Dabbous
Senior Director, Health Economics and Outcomes Research, Takeda Pharmaceuticals
Key conference topics:
  • Share best practices with peer companies about creating, accessing and utilizing pharmacoeconomics data
  • Incorporate key strategies to strenghten and promote the value of your product or process
  • Hear from the payer community about what type of data they want to see from life sciences companies
  • Discuss the future impact of both CER and overarching healthcare reform and how to prepare
Full details at http://www.marcusevansch.com/HEOR_BTB

The Journal of Commercial Biotechnology is proud to announce the addition of two esteemed industry experts to its advisory board.

The new editorial board members are:

  • Ananda Mohan Chakrabarty, distinguished university professor at the University of Illinois at Chicago and noted for his genetically modified Pseudomonas bacteria that became the first genetically-engineered organism to gain a US patent as a result of the Supreme Court decision in Diamond vs. Chakrabarty. He is the co-founder of two companies, CDG Therapeutics Inc. in Chicago and Amrita Therapeutics in India.
  • Meir Perez Pugatch, Managing Director Pugatch Consilium; Chair, Division of Health Systems Administration, School of Public Health, University of Haifa, Israel

These esteemed individuals complement the existing editorial advisory board, which includes:

  • Mark Ahn, Principal, Pukana Partners, Ltd., USA, United States
  • John Avellanet, Cerulean Associates LLC, United States
  • Boris Bogdan, Partner, Avance, Basel GmbH, Switzerland
  • Arthur Boni, John R. Thorne Chair of Entrepreneurship; Associate Teaching Professor of Entrepreneurship; and Director, Donald H. Jones Center for Entrepreneurship, Tepper School of Business, Carnegie Mellon University, United States
  • Walter Bratic, Managing Director, Overmont Consulting LLC, United States
  • G. Steven Burrill, Chief Executive Officer, Burrill & Company, United States
  • Steven Casper, Henry E. Riggs Professor of Management, Keck Graduate Institute of Applied Life Sciences, United States
  • Vijay Chandra, Chairman & CEO, Strand Life Sciences Pvt Ltd, India and Consulting Professor, ISL/EE, Stanford University, United States
  • James Class, Director, Global Public Policy, Merck, United States
  • Jeremy Laurence Curnock Cook, Executive Chairman, Bioscience Managers Limited, United Kingdom
  • Iraj Daizadeh, Senior Manager, Amgen Inc, United States
  • Mitch DeKoven, Director – Reimbursement and Market Access, Health Economics & Outcomes Research, IMS Health, United States
  • Spencer G. Feldman, Shareholder, Greenberg Traurig, United States
  • Sharon Finch, Director, Medius Associates, United Kingdom
  • Hernan Garrido-Lecca, Chairman and CEO Bioinvest; Professor of Economics and Public Policy, Universidad de San Martín de Porres, Lima Peru and Former Minister of Health, Peru
  • Gerald S. Graham, Business and Management Consultant, Graham Consulting Group, United States
  • Dave Jensen, Managing Director, CareerTrax Inc., United States
  • Kenneth Kaitin, Director, Tufts Center for the Study of Drug Development and Professor of Medicine, Tufts University School of Medicine, United States
  • John Khong, Owner, Niche Medical, J & M Technologies, Cell Sciences; Adjunct faculty, LKC Business School, Singapore management University, Singapore
  • Edward L. Korwek, Partner, Hogan Lovells, United States
  • Thomas J. Kowalski, Attorney at Law, Vedder Price P.C., United States
  • Leonard Lerer, Sudarskis & Partners, United Arab Emirates
  • Weijun Li, Senior Research Scientist, Global Biological Development, Bayer HealthCare Pharmaceuticals, United States
  • Bryan A. Liang, Professor of Anesthesiology & Director San Diego Center for Patient Safety, University of California San Diego School of Medicine; Professor of Law & Executive Director, Institute of Health Law Studies, California Western School of Law, United States
  • Kate Lynch, CEO, Generic Medicines Industry Association (GMiA), Australia
  • Barry Marenberg, Chief Intellectual Property Strategist, BJM BioPat Solutions, United States
  • Henry I. Miller, Senior Research Fellow of Scientific Philosophy & Public Policy, Hoover Institution, Stanford University, United States
  • Stefan Michael Miller, Associate, Dechert LLP, United States
  • Sudha Nair, Director, Global Business Development, Apotex Fermentation Inc., Canada
  • Robin Nott, Chair of the Laws Committee, Licensing Executives Society Britain and Ireland, United Kingdom
  • Meir Perez Pugatch, Chair Division of Health Systems Administration, School of Public Health, University of Haifa; Managing Director Pugatch Consilium, Israel
  • Rebecca Robins, Director, Europe, Business Development, Interbrand Wood Healthcare, United Kingdom
  • Anthony J Russo, Chairman and CEO, Russo Partners, United States
  • Stephen M. Sammut, Senior Fellow, Wharton Health Care Systems and Entrepreneurial Programs and Venture Partner, Burrill & Company, United States
  • Simon Shohet, Practice Director, Pope Woodhead & Associates Ltd, United Kingdom
  • Grant Skrepenk, Assistant Professor, The University of Arizona College of Pharmacy and Investigator, Center for Health Outcomes and PharmacoEconomic Research, United States
  • Anthony Stevens, Director, Medical Options, United Kingdom
  • Philip Neal Sussman, Managing Partner, The Channel Group LLC, United States
  • Michael Vitale, Director of Commercialisation, Monash Asia-Pacific Centre for Science and Wealth Creation, Monash University, Australia
  • Stan Yakatan, Chairman, Katan Associates, United States

For more information, see the Journal of Commercial Biotechnology at http://CommercialBiotechnology.com